http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
-
Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases
-
Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases
-
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting
-
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting
-
Cue Biopharma Inc. (CUE) Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT
-
Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT
-
Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT
-
Cue Biopharma (CUE) Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
-
Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
-
Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
-
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights
-
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
-
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
-
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
-
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
-
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC
-
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC
-
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting
-
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting
-
Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference
-
Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference
-
Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights
-
Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma (CUE) Reports Confirmed Partial Response in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
-
Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
-
Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
-
Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference
-
Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference
-
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
-
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
-
Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference
-
Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference
-
Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference
-
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
-
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
-
Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference
-
Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference
-
Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

